Background: This study was conducted to dosimetrically compare plan quality of Simultaneous Integrated Boost – Stereotactic Body Radiotherapy (SIB-SBRT) generated for different techniques such as Cyberknife (CK), Helical Tomotherapy (HT) and RapidArc (RA) for carcinoma prostate with same treatment margins. Materials and Methods: SIB-SBRT plans were generated for CK, HT and RA for thirteen CT data sets. The dose prescription was 45Gy in 5 fractions to GTV45 and 37.5Gy in 5 fractions to PTV37.5. The plan quality evaluation of the three techniques was done by comparing the DVH parameters, conformity index (CI) and gradient index (GI). For OAR’s mean, maximum dose and dose volumes were compared for bladder, rectum and bilateral femoral heads. The number of Monitor Units (MU) delivered and Beam-on time (BOT) were also compared. Results: D2%, D50% and DMean to GTV45 was significantly higher in the CK compared to HT and RA (CK vs HT: p values, 0.001, 0.002 and 0.003; CK vs RA: p values, 0.001, 0.004 and 0.004) respectively. RA gives a better gradient index compared to CK and HT. Conformity indices of the RA plans were better than the CK plans (P0.001). Normal tissue and integral dose delivered to the patient in HT and CK were found to be significantly higher than RA. The average number of MU’s and BOT were significantly higher in CK (p0.001). Conclusion: Using the same treatment margins and dose constraints, RA achieved better target dose distribution and sparing of critical structures compared to CK and HT. RA seemed to be the optimal planning technique for SIB-SBRT treatment of carcinoma prostate.
展开▼
机译：背景：本研究的目的是同时集成升压的剂量测定比较计划质量 - 对于不同的技术，如射波刀（CK），螺旋断层放疗（HT）和的RapidArc（RA），用于癌前列腺具有相同生成立体定向体放射治疗（SIB-SBRT）治疗利润率。为CK，HT和RA了十个CT数据集生成SIB-SBRT计划：材料和方法。所述剂量处方为为45Gy在5个馏分GTV45和37.5Gy在5个馏分PTV37.5。的三种技术的计划质量评价通过比较DVH参数，一致性指数（CI）和梯度折射率（GI）来完成。对于OAR的平均，最大剂量和剂量体积膀胱，直肠及双侧股骨头相比。监控单元（MU）的数量和交付光束开启时间（BOT）进行了比较。结果：D2％，D50％和DMEAN到GTV45是显著高于在CK相比HT和RA（CK VS HT：P值<0.001，0.002和0.003; CK VS RA：P值，0.001，0.004和0.004）分别。 RA给出比对照和HT更好的梯度折射率。的RA计划合格指标均低于CK计划（P <0.001）更好。正常组织和交付给HT和CK患者累积剂量被认为是比RA显著高。 MU的和BOT的平均数在CK（P <0.001）是显著高。结论：使用相同的治疗边距和剂量约束，RA实现更好的目标剂量分布，并且与CK和HT关键结构的备用。 RA似乎是SIB-SBRT治疗前列腺癌的最佳规划技术。
展开▼
